Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

PC319L Anti-Heparin Binding Epidermal Growth Factor (Ab-1) Goat pAb

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-HB-EGF

View Products on Sigmaaldrich.com
PC319L
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
HGtPolyclonal Antibody
Description
Overview

This product has been discontinued.



Recognizes the ~19-23 kDa HB-EGF protein in vascular smooth muscle cells.
Catalogue NumberPC319L
Brand Family Calbiochem®
SynonymsAnti-HB-EGF
References
ReferencesDavis-Fleischer, K.M. et al. 1998. Front. Biosci. 3, D288.
Ouchi, N., et al. 1997. Biochem. J. 328, 923.
Raab, G. and Klagsbrun M. 1997. Biochim. Biophys. Acta 1333, F179.
Suzuki, M., et al. 1997. J. Biol. Chem. 272, 31730.
Nakata, A., et al. 1996. Circulation 94, 2778.
Miyagawa, J., et al. 1995. J. Clin. Invest. 95, 404.
Product Information
FormLyophilized
FormulationLyophilized from sterile filtered solution in PBS, 5% trehalose, 100 µg BSA.
Positive controlVascular smooth muscle cells
PreservativeNone
Quality LevelMQ100
Applications
Key Applications Enzyme-Linked Immunosorbent Assay
Immunoblotting (Western Blotting)
Neutralization Studies
Application NotesELISA (0.5-1 µg/ml, see comments)
Immunoblotting (1-2 µg/ml)
Neutralization Studies (see comments)
Application CommentsThis antibody has been selected for its ability to neutralize the biological activity of human recombinant HB-EGF. It will not neutralize the biological activity of EGF, TGF-α or amphiregulin. The exact concentration of antibody required to neutralize human recombinant HB-EGF activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied. Suggested neutralization concentration required to yield one-half maximal inhibition of HB-EGF activity is ~3-6 µg/ml in the presence of 10 ng/ml of human recombinant HB-EGF using a Balb/3T3 cell line. For immunoblotting, the detection limit for human recombinant HB-EGF is ~0.5 ng/lane under non-reducing and reducing conditions. For ELISA, the detection limit for human recombinant HB-EGF is ~0.03 ng/well. This antibody exhibits no cross-reactivity with other cytokines when tested in ELISA. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenpurified, recombinant, human HB-EGF
ImmunogenHuman
HostGoat
IsotypeIgG
Species Reactivity
  • Human
Antibody TypePolyclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful
Storage -20°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsReconstitute the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 0.25 mg/ml. Lyophilized antibody should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Avoid freeze/thaw cycles of solutions.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
PC319L 0

Documentation

Anti-Heparin Binding Epidermal Growth Factor (Ab-1) Goat pAb SDS

Title

Safety Data Sheet (SDS) 

Anti-Heparin Binding Epidermal Growth Factor (Ab-1) Goat pAb Certificates of Analysis

TitleLot Number
PC319L

References

Reference overview
Davis-Fleischer, K.M. et al. 1998. Front. Biosci. 3, D288.
Ouchi, N., et al. 1997. Biochem. J. 328, 923.
Raab, G. and Klagsbrun M. 1997. Biochim. Biophys. Acta 1333, F179.
Suzuki, M., et al. 1997. J. Biol. Chem. 272, 31730.
Nakata, A., et al. 1996. Circulation 94, 2778.
Miyagawa, J., et al. 1995. J. Clin. Invest. 95, 404.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision09-October-2007 RFH
SynonymsAnti-HB-EGF
ApplicationELISA (0.5-1 µg/ml, see comments)
Immunoblotting (1-2 µg/ml)
Neutralization Studies (see comments)
DescriptionPurified goat polyclonal antibody. Recognizes the ~19-23 kDa (apparent MW) heparin binding epidermal growth factor protein.
BackgroundHeparin-binding epidermal growth factor-like growth factor (HB-EGF) is a ~22 kDa O-glycosylated protein that is a potent mitogen and chemoattractant for vascular smooth muscle cells, fibroblasts and epithelial cells but not endothelial cells. The natural protein has an apparent molecular mass of ~19-23 kDa and exists in multiple forms as a result of heterogeneous O-glycosylation and/or N-terminal truncation. HB-EGF is synthesized as a membrane-anchored precursor (proHB-EGF) that is proteolytically cleaved to release the soluble mature growth factor. The two forms are active as juxtacrine and paracrine/autocrine growth factors respectively. Recent studies show MMP-3 as one of the enzymes that cleaves HB-EGF implicating a role for MMP-3 in the regulation of HB-EGF from being a juxtacrine to a paracrine/autocrine factor. HB-EGF activates two EGF receptor subtypes, HER1/ErbB1 and HER4 and binds to heparan sulfate proteoglycan. The proHB-EGF is postulated as the high affinity receptor for diphtheria toxin (DT). Recent evidence suggests that the coexpression of proHB-EGF and CD9 on macrophages may strongly promote the development of atherosclerosis by a juxtacrine mechanism. Transcription of HB-EGF can be induced in vascular endothelial cells as well as aortic smooth muscle cells which may also play an important role in the pathogenesis of atherosclerosis.
HostGoat
Immunogen speciesHuman
Immunogenpurified, recombinant, human HB-EGF
IsotypeIgG
Specieshuman
Positive controlVascular smooth muscle cells
FormLyophilized
FormulationLyophilized from sterile filtered solution in PBS, 5% trehalose, 100 µg BSA.
PreservativeNone
CommentsThis antibody has been selected for its ability to neutralize the biological activity of human recombinant HB-EGF. It will not neutralize the biological activity of EGF, TGF-α or amphiregulin. The exact concentration of antibody required to neutralize human recombinant HB-EGF activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied. Suggested neutralization concentration required to yield one-half maximal inhibition of HB-EGF activity is ~3-6 µg/ml in the presence of 10 ng/ml of human recombinant HB-EGF using a Balb/3T3 cell line. For immunoblotting, the detection limit for human recombinant HB-EGF is ~0.5 ng/lane under non-reducing and reducing conditions. For ELISA, the detection limit for human recombinant HB-EGF is ~0.03 ng/well. This antibody exhibits no cross-reactivity with other cytokines when tested in ELISA. Antibody should be titrated for optimal results in individual systems.
Storage Avoid freeze/thaw
-20°C
Do Not Freeze Ok to freeze
Special InstructionsReconstitute the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 0.25 mg/ml. Lyophilized antibody should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Avoid freeze/thaw cycles of solutions.
Toxicity Harmful
ReferencesDavis-Fleischer, K.M. et al. 1998. Front. Biosci. 3, D288.
Ouchi, N., et al. 1997. Biochem. J. 328, 923.
Raab, G. and Klagsbrun M. 1997. Biochim. Biophys. Acta 1333, F179.
Suzuki, M., et al. 1997. J. Biol. Chem. 272, 31730.
Nakata, A., et al. 1996. Circulation 94, 2778.
Miyagawa, J., et al. 1995. J. Clin. Invest. 95, 404.